CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Caremark negotiated an undisclosed lower net ... meaning they can still decide to include Zepbound. Regardless, the CVS-Wegovy deal overshadowed an overall strong quarter for Eli Lilly.

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

One of the largest benefit managers, CVS Health’s Caremark, made the decision to exclude Zepbound in spite of research that found that it resulted in more weight loss than Wegovy, which will ...